Esophageal Intraepithelial Neutrophil Infiltration is Common in Nigerian Patients With Non-Erosive Reflux Disease

Sylvester Chucks Nwokediuko\textsuperscript{a, c}, Uchenna Ijom\textsuperscript{a}, Okechukwu Okafor\textsuperscript{b}

Abstract

**Background:** Non-erosive reflux disease (NERD) is a variant of gastroesophageal reflux disease (GERD) in which patients with typical reflux symptoms have no evidence of erosive esophagitis at endoscopy. An objective diagnostic tool for NERD remains an unmet need for clinicians and researchers. This study was designed to determine the types of histological alterations seen in Nigerian patients with NERD.

**Methods:** This was a prospective cross-sectional study in which mucosal biopsy was taken from the lower esophagus in patients with NERD. Similar biopsy was also taken from patients with non-ulcer dyspepsia who served as controls. The materials were processed and examined histologically.

**Results:** There were 68 patients with NERD and 60 patients with nonulcer dyspepsia. Intraepithelial neutrophil infiltration was significantly more frequent in patients with NERD compared to those with nonulcer dyspepsia (47.1% vs 13.3%, \( P = 0.0326 \)). Epithelial proliferative changes in the form of basal cell hyperplasia and papilla elongation were minimal (11.8% and 3.3% respectively).

**Conclusions:** Nigerian patients with NERD have a high degree of esophageal intraepithelial neutrophil infiltration and a low prevalence of epithelial proliferative changes. This may be related to the relative rarity of Barrett’s esophagus in Nigerians.

Keywords: Intraepithelial; Neutrophil; Esophagus; NERD; Nigerians

Introduction

Gastroesophageal reflux disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms with or without mucosal damage, and/or complications. Heartburn and regurgitation are typical symptoms of reflux experienced by patients [1, 2]. The prevalence of GERD is highest in North America and Europe, where at least weekly reflux symptoms range from 10 to 30%. Epidemiologic data are limited but suggest a lower prevalence in Asia [3], although prevalence is increasing in this region and other developed countries [4]. Gastroesophageal reflux disease was previously thought to be rare in Africans but recent studies actually indicate that it is common [5].

The disease adversely affects health-related quality of life [6], and the majority of patients (> 60%) with typical reflux symptoms have no evidence of erosive esophagitis at endoscopy [7, 8]. Such patients are usually considered to have non-erosive reflux disease or NERD [9].

Traditionally, GERD has been approached as a spectrum with NERD at the mild end and complicated GERD (stricture, Barrett’s esophagus or adenocarcinoma) at the other end of the spectrum. However recent data indicate that GERD may be categorized into three unique groups of patients or phenotypes: those with NERD, those with erosive esophagitis and those with Barrett’s esophagus [10].

The accurate assessment of NERD has proved difficult, as endoscopy does not provide any useful information, symptoms may be variable or atypical and even prolonged monitoring of esophageal pH shows no abnormality in about one-third of patients with otherwise typical symptoms [11]. Therefore, an objective diagnostic tool with acceptable sensitivity remains an unmet need for clinicians and researchers.

Over the years, various histological lesions have been described in patients with NERD. These studies were carried out in mainly Caucasian populations [12-14]. No such
study has been done on Nigerians with NERD. Patients with NERD constitute over 60% of GERD in Nigeria [8]. This study was designed to determine the type and frequency of histological changes in the esophageal mucosa seen in Nigerian patients with NERD.

Materials and Methods

This was a prospective cross-sectional study of patients with upper gastrointestinal symptoms seen at the gastroenterology unit of the University of Nigeria Teaching Hospital (UNTH) Ituku/Ozalla and Uzoma Specialist Hospital Trans Ekulu Enugu from June 2009 to December 2010. The study protocol was approved by the UNTH research ethics committee and informed consent was obtained from all the participants.

Patients who had heartburn and/or regurgitation were administered the Carlsson-Dent (CD) questionnaire [15]. This questionnaire utilized a symptom description and symptom analysis with numerical scores assigned to specific components of the symptom analysis. These scores could be positive or negative. When summed up, the total ranged from -7 to +18. The severity of symptoms was also graded from 1 to 5 representing no problem at all, mild problem, moderate problem, severe problem and very severe problem. The conditions for a diagnosis of GERD were a total score of 4 or higher in the CD questionnaire [15], and mild symptoms occurring on 2 or more days a week or more severe symptoms occurring at least once a week [2, 16]. Those diagnosed with GERD on this schema had standard upper gastrointestinal (GI) endoscopy and if no endoscopic lesion was found in the esophagus a diagnosis of NERD was made. Five mucosal biopsies were obtained from the lower esophageal area about 2 cm above the squamo-columnar junction (SCJ) around the 3 o’clock position.

Patients whose symptoms were epigastric pain, epigastric burning, postprandial fullness and/or early satiation were grouped as dyspepsia complex in accordance with Rome III guidelines [17, 18]. They also underwent upper GI endoscopy and if no endoscopic lesion was found in the esophagus a diagnosis of NERD was made. Five mucosal biopsies were obtained from the lower esophageal area about 2 cm above the squamo-columnar junction (SCJ) around the 3 o’clock position.

Table 1. Gender Distribution of Patients With Upper Gastrointestinal Symptoms

| Group          | Male | Female | Total |
|----------------|------|--------|-------|
| NERD           | 28   | 40     | 68    |
| Functional Dyspepsia | 27   | 33     | 60    |
| Total          | 55   | 73     | 128   |

Patients who had a combination of symptoms suggestive of GERD and dyspepsia were excluded from the study. Also excluded were patients who had hiatus hernia regardless of whether they had dyspeptic or reflux symptoms.

All the esophageal biopsy specimens were properly labeled, fixed in 10% buffered formalin, processed using paraffin embedding technique, sectioned at 4 micrometer perpendicular to the mucosal surface and stained with hematoxylin and eosin (H&E). Histological examination was performed by the same pathologist who was blind to the clinical diagnosis. The parameters scored were basal cell hyperplasia, papilla elongation, inflammation and dilated intercellular spaces. A score of 2 was regarded as the optimal cut-off value for separating GERD from non-GERD patients [19]. The results were expressed as means and proportions. Differences between means and proportions were determined and P values < 0.05 were considered statistically significant. A test of correlation was also carried out between the clinical criteria (score on CD questionnaire) and the histological criteria (reflux score) for the patients with NERD.

Results

One hundred and twenty-eight (128) patients with upper GI symptoms participated in the study (68 patients with NERD and 60 patients with dyspepsia). There were 55 males (43.0%) and 73 females (57.0%). Table 1 illustrates the gender distribution of the patients. The mean age of patients with NERD was 51.8 ± 14.4 years while the mean age of the dyspeptic patients was 50.6 ± 14.8 years. The difference between the two means was not statistically significant (P = 0.9899). Table 2 illustrates the histological parameters. Dilated intercellular spaces (DIS) and intraepithelial neutrophil infiltration were the morphological changes that occurred more frequently in the patients with NERD compared to their dyspeptic counterparts. The difference was statistically significant (P = 0.0121 and 0.0326 respectively). Similarly, the mean reflux score in the patients with NERD was 2.29 ± 2.14 while the mean reflux score in the dyspeptic patients was 0.7 ± 0.7944. The difference was statistically significant (P = 0.0036). Using histological criteria for the diagnosis of GERD as proposed by Zentilin et al [19], 42 NERD patients...
(61.8%) qualified for a diagnosis of GERD while only 6 dyspeptic patients (10%) qualified for such diagnosis. The difference was statistically significant (P = 0.003).

A positive correlation was demonstrated between the clinical and histological criteria [Pearson (γ) = 0.7767, P < 0.0001]. Thirty-two females had reflux scores ≥ 2 (43.8%), while only 10 males had reflux scores ≥ 2 (18.2%).

**Discussion**

This study describes the histological changes in Nigerians with NERD using patients with functional dyspepsia as controls. Dilatation of intercellular spaces (DIS) was demonstrated in 41.2% of NERD patients compared to 6.7% of dyspeptic patients (P = 0.0121). It is one of the earliest changes resulting from acid injury to the esophageal epithelium and is the commonest morphological alteration seen in GERD. It has been proposed as a sensitive marker of acid-induced damage in the squamous epithelium. The description of this individual lesion, identifiable both by electron [20-22] and light microscopy [23, 24], has provided a stimulus for clinicians to reconsider histology in the diagnosis of GERD. It is not only more common in NERD patients compared to controls, but has also shown to improve after treatment with acid suppression [25]. However, there are concerns regarding the specificity of DIS as it is also found in association with psychological stress in animal models [26].

The remarkable finding in this study is the high prevalence of intraepithelial neutrophil infiltration in NERD patients. Inflammatory cells have previously been reported as rare in NERD [27]. Inflammation of any type (lymphocytes, eosinophils and neutrophils) had been adjudged to be more specific than sensitive for the diagnosis of reflux esophagitis [28, 29]. Neutrophils are the most abundant circulating leukocytes and they provide the first line of defense against tissue injury or infection. They release soluble chemotactic factors and proteases that alter the microenvironment and guide the recruitment of both nonspecific and specific immune effector cells [30]. Inflammatory and other immune cells undoubtedly take part in anti-tumor surveillance. In the absence of certain cells or functions, it is possible that some tumors will progress more rapidly [31-33]. Some studies have suggested that neutrophils are active in immunosurveillance against several tumors [34-36].

The histological changes in GERD generally and NERD specifically may be the forerunners of more serious complications such as Barrett’s esophagus. Barrett’s esophagus is known to exhibit racial variation, being more common in whites than blacks [37]. The significance of intraepithelial neutrophils is not clear but may be related to the relative rarity of Barrett’s esophagus in Nigerians and indeed blacks. Furthermore, changes of epithelial proliferation (basal cell hyperplasia and papilla elongation) were not common in NERD patients in this study. However, some studies have also shown that tumor-associated monocytes/macrophages are essential promoters of tumor cell migration, invasion and metastasis [38]. Inflammation is now considered a well-established cancer risk factor; a number of inflammatory conditions predispose to cancer, including ulcerative colitis and Barrett’s esophagus [39]. So it is not surprising that the regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is related to a decreased risk of several types of cancer. Compelling data from epidemiological studies, intervention trials and animal studies indicate that aspirin and other NSAIDs inhibit colorectal carcinogenesis [40, 41]. Epidemiological evidence is accumulating that aspirin or NSAID use is protective against esophageal and gastric cancer, and possibly also against cancers of prostate, ovary and lung [42-47]. More studies, including genetic studies, are clearly needed not only to further elucidate the significance of intraepithelial neutrophil infiltration in NERD but

### Table 2. Histological Parameters (Esophageal Biopsy) in NERD and Dyspeptic Patients

| Histological Parameter                        | NERD (n = 68) | Functional Dyspepsia (n = 60) | P value |
|----------------------------------------------|--------------|-----------------------------|---------|
| Basal Cell Hyperplasia                       | 8 (11.8%)    | 2 (3.3%)                    | 0.2446  |
| Papilla Elongation                           | 8 (11.8%)    | 2 (3.3%)                    | 0.2446  |
| Dilated Intercellular Spaces                 | 28 (41.2%)   | 4 (6.7%)                    | 0.0121* |
| Eosinophils                                  | 4 (5.9%)     | 2 (3.3%)                    | 0.6457  |
| Neutrophils                                  | 32 (47.1%)   | 8 (13.3%)                   | 0.0326* |
| Mean Score                                   | 2.29 ± 2.14  | 0.7 ± 0.7944                | 0.0036* |
| Score ≥ 2                                    | 42 (61.8%)   | 6 (10%)                     | 0.003*  |

*Statistically significant
also to determine the benefits and deleterious effects of inflammation in carcinogenesis.

There were more females (57%) than males (43%) in the population studied. Similarly, the relative proportion of females who had a reflux score (histology) of ≥2 was higher than the relative proportion of males (43.8% versus 18.2%). This is consistent with findings from other studies across the globe. There is a consistent female preponderance in dyspepsia [48-52] and patients with NERD often have other functional gastrointestinal symptoms, such as functional dyspepsia and irritable bowel syndrome (IBS), with a frequency higher than observed in most studies of erosive reflux disease [53-55].

In conclusion we have demonstrated that Nigerian patients with NERD have a high prevalence of esophageal intraepithelial neutrophil infiltration and a low prevalence of epithelial proliferative changes. It remains to be shown whether these changes are related to the observed relative rarity of Barrett’s esophagus in Nigerian patients with GERD.

References

1. Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008;23(1):8-22.
2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900-1920; quiz 1943.
3. Sharma P, Wani S, Romero Y, Johnson D, Hamilton F. Racial and geographic issues in gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2005;20(8):1552-1562.
4. El-Serag HB. Time trends of gastroesophageal reflux disease in the United States and Canada: a systematic review. Clin Gastroenterol Hepatol 2007;5(1):17-26.
5. Segal I. The gastro-oesophageal reflux disease complex in sub-Saharan Africa. Eur J Cancer Prev 2001;10(3):209-212.
6. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22(2):108-114.
7. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Graffner H, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005;40(3):275-285.
8. Nwokediuko S, Ijomah U, Obienu O, Agunyewa C: Gastroesophageal Reflux Disease A Clinical And Endoscopic Study Of Nigerian Patients. The Internet Journal of Gastroenterology 2009;8(2).
9. Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE, eds. Rome III: The Functional Gastrointestinal Disorders, 3rd edn. McLean, VA: Deegon Associates, Inc., 2006.
10. Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004;19 Suppl 1:28-34.
11. Quigley EM. 24-h pH monitoring for gastroesophageal reflux disease: already standard but not yet gold? Am J Gastroenterol 1992;87(9):1071-1075.
12. Ismail-Beigi F, Horton PF, Pope CE, 2nd. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970;58(2):163-174.
13. Brown LF, Goldman H, Antonioli DA. Intraepithelial eosinophils in endoscopic biopsies of adults with reflux esophagitis. Am J Surg Pathol 1984;8(12):899-905.
14. Ballem CM, Fletcher HW, Mc Cr. The diagnosis of esophagitis. Am J Dig Dis 1960;5:88-93.
15. Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, Riley S, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33(10):1023-1029.
16. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006;101(1):18-28.
17. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130(5):1377-1390.
18. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006;15(3):237-241.
19. Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dubecco P, Cepa P, Savarino E, et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 2005;100(10):2299-2306.
20. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003;18(5):525-532.
21. Calabrese C, Fabbri A, Bortolotti M, Cenacchi G, Arneri A, Scialpi C, Miglioli M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003;18(5):525-532.
22. Caviglia R, Ribolisi M, Maggiano N, Gabbielli AM, Emerenziani S, Guarino MP, Carotti S, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal
acid exposure. Am J Gastroenterol 2005;100(3):543-548.
23. Solcia E, Villani L, Luinetti O, Trespi E, Strada E, Tinelli C, Fiocca R. Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch 2000;436(3):207-216.
24. Villanacci V, Grigolato PG, Cestari R, Missale G, Cenia G, Klersy C, Rindi G. Dilated intercellular spaces as markers of reflux disease: histology, semiquantitative score and morphology upon light microscopy. Digestion 2001;64(1):1-8.
25. Armstrong D, Vieth M, Fiocca R, Deprez P, Kuiipers E, Holmquist L, Junghard O et al. Are endoscopy-negative GERD and reflux esophagitis different diseases? Baseline histology in GERD patients off-therapy - the CHEER study. Gastroenterology 2003;124:A-416.
26. van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008;103(4):1021-1028.
27. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007;5(1):4-16.
28. Vieth M, Peitz U, Labenz J, Kulig M, Naessler E, Jasperse D, Meyer-Sabellek W, et al. What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett’s mucosa? Dig Dis 2004;22(2):196-201.
29. Haggitt RC. Histopathology of reflux-induced esophageal and supraspinal injuries. Am J Med 2000;108 Suppl 4a:109S-111S.
30. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97(2):339-345.
31. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13(11):1382-1397.
32. Rothenberg ME. Eosinophilia. N Engl J Med 1998;338(22):1592-1600.
33. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2(10):737-744.
34. Midorikawa Y, Yamashita T, Sendo F. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res 1999;50(19):6243-6247.
35. Matsumoto Y, Saiki I, Murata J, Okuyama H, Tamura M, Azuma I. Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice. Int J Cancer 1991;49(3):444-449.
36. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorogenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173(4):889-897.
37. Spechler SJ. Epidemiology and natural history of gastro-esophageal reflux disease. Digestion 1992;51 Suppl 1:24-29.
38. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124(2):263-266.
39. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-867.
40. Giovannucci E. The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 1999;53(7):303-308.
41. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23(12):2840-2855.
42. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124(1):47-56.
43. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004;90(1):93-99.
44. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95(23):1784-1791.
45. Holick CN, Michaud DS, Leitzmann MF, Willett WC, Giovannucci E. Aspirin use and lung cancer in men. Br J Cancer 2003;89(9):1705-1708.
46. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marco AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26(7):1170-1181.
47. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 2003;37:1-24.
48. Shaib Y, El-Serag HB. The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. Am J Gastroenterol 2004;99(11):2210-2216.
49. Kay L, Jorgensen T. Epidemiology of upper dyspepsia and non-ulcer dyspepsia: emerging insights. Carcinogenesis 1994;15(3):735-740.
Caballero FJ, Lopez-Manas JG. Irritable bowel syndrome in patients with dyspepsia: a community-based study in southern Europe. Eur J Gastroenterol Hepatol 1999;11(5):517-522.

51. Lu CL, Lang HC, Chang FY, Chen CY, Luo JC, Wang SS, Lee SD. Prevalence and health/social impacts of functional dyspepsia in Taiwan: a study based on the Rome criteria questionnaire survey assisted by endoscopic exclusion among a physical check-up population. Scand J Gastroenterol 2005;40(4):402-411.

52. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol 2002;97(9):2290-2299.

53. Jung HK, Halder S, McNally M, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007;26(3):453-461.

54. De Vries DR, Van Herwaarden MA, Baron A, Smout AJ, Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease. Scand J Gastroenterol 2007;42(8):951-956.

55. Stanghellini V, Barbar G, Cogliandro R, Salvioli B, Cremon C, Di Giorgio R, Corinaldesi R. Overlap between GERD and IBS: irrefutable but subtle. J Clin Gastroenterol 2007;41(suppl 2):S114-S117.